

# Vascular remodelling in intramyocardial resistance vessels in hypertensive human cardiac transplant recipients

John T Jenkins, Joseph J Boyle, Ian C McKay, David Richens, Allan R McPhaden, George B M Lindop

## Abstract

**Objective**—Cardiac transplant recipients often develop hypertension as a side effect of immunosuppressive treatment. The aim of this study was to use the serial endomyocardial biopsies taken to monitor rejection to study the early and sequential arterial changes in human myocardial resistance arteries as hypertension develops.

**Methods**—At least 14 biopsies were studied from each of 23 patients, divided into a normotensive group (12 patients with a diastolic pressure never greater than 90 mm Hg) and a hypertensive group (11 patients with more than 10% of diastolic pressure measurements above 100 mm Hg). Morphometric analysis of between 30 and 50 arteries and arterioles in two widely separated histological levels from each biopsy was undertaken using an Optomax image analyser.

**Results**—There was a correlation between blood pressure, particularly diastolic pressure, and rate of medial thickening of intramyocardial coronary resistance arteries and arterioles ( $P = 0.0025$ ). There was also a correlation between serum cyclosporin A concentrations and mean artery wall thickness ( $P = 0.003$ ).

**Conclusions**—Hypertension and cyclosporin A treatment are associated with significant wall thickening of intramyocardial resistance vessels in cardiac allograft recipients. These changes may be functionally and clinically important.

(Heart 1997;77:353-356)

**Keywords:** artery remodelling; hypertension; cyclosporin A; cardiac transplant

In hypertension, medial thickening is the earliest structural change in arteries.<sup>1,2</sup> There is intense interest in its pathogenesis because medial thickening may give rise to an accentuated response to prevailing pressor stimuli—the “vascular amplifier” of early hypertension.<sup>3</sup> Medial thickening with increased wall to lumen ratio could result from smooth muscle cell hypertrophy, hyperplasia, or increased overlap of the same number of smooth muscle cells of the same size (remodelling). These processes may occur in isolation or in concert, but their relative contributions remain uncertain.<sup>4,5</sup>

Cardiac transplant recipients often become

hypertensive largely because the immunosuppressive agents cyclosporin A and glucocorticoids raise blood pressure as a dose related side effect.<sup>6</sup> Since serial endomyocardial biopsies are examined microscopically to monitor rejection, there is a unique opportunity to study the early and sequential arterial changes in human myocardial resistance vessels as hypertension develops. Diagnostic endomyocardial biopsies have been used to assess the thickness of intramyocardial arteries in essential hypertension by morphometry.<sup>7,8</sup> Similar studies have not been undertaken in the cardiac transplant population, nor has hypertensive vascular disease been studied longitudinally with time, either in animals or in man. We elected to use serial cardiac allograft biopsies to quantify the changes in arterial geometry that occur in the early phases of hypertension in man.

## Methods

### PATIENTS

Twenty three orthotopic cardiac transplant recipients were selected from the files of the Scottish Cardiopulmonary Transplant Centre. To maximise the separation in blood pressure we selected 11 patients with diastolic blood pressure that was often (more than 10% of measurements) more than 100 mm Hg, and 12 patients with diastolic blood pressure never more than 90 mm Hg. The former group was considered to be hypertensive and the patients were treated as clinically indicated; the latter group was considered to be normotensive. They accounted in total for approximately half of the transplant recipients at this centre. The two groups of patients were matched for age, sex, number and severity of rejection episodes, and immunosuppressant drug treatment. Also available were monthly blood pressure measurements, doses of glucocorticoids, serial cyclosporin A serum concentrations, and donor age and sex.

### TISSUE PROCESSING AND MORPHOMETRIC ANALYSIS

Endomyocardial biopsies were fixed by immersion in formalin, processed into paraffin wax, and sectioned at 4  $\mu$ m. Sections were coded by random numbering to ensure ignorance of their temporal sequence and patient details. All arteries and arterioles were measured by one observer (JJ) provided they satisfied the following criteria: a complete layer of smooth muscle cells in the media; a visible lumen; and no histological abnormalities or artefacts. Vessels were

University of Glasgow  
Department of  
Pathology, Western  
and Royal Infirmaries,  
Glasgow

J T Jenkins

J J Boyle

A R McPhaden

G B M Lindop


University of Glasgow  
Department of  
Immunology, Western  
Infirmary, Glasgow  
I C McKay

Scottish  
Cardiopulmonary  
Transplant Centre,  
Royal Infirmary,  
Glasgow  
D Richens


Correspondence to:  
Dr G B M Lindop,  
University of Glasgow  
Department of Pathology,  
Western Infirmary, Glasgow  
G11 6NT, United Kingdom.

Accepted for publication  
24 January 1997


**Figure 1**  
Photomicrograph of a cross section of a small intramyocardial coronary artery. The coordinate points used for artery measurement are superimposed on the artery. Haematoxylin and eosin  $\times 250$ .



excluded if they were situated in regions of rejection, scarring, previous biopsy site, organising thrombus, or epicardial fat. Between 30 and 50 arteries and arterioles from two widely separated histological sections from a minimum of 14 biopsies from each of the patients were subjected to morphometric analysis. This was carried out using an Optomax image analyser (AMJ) interfaced to an IBM PS2 computer run-



**Figure 2** Scattergram in which the x axis represents the diastolic blood pressure (DBP) for each patient, averaged over the course of the study. The y axis shows the rate of change in log mean wall thickness of each patient's intramural coronary arteries. It is derived from the gradient of the regression line which best fitted the scattergram of each biopsy's log mean wall thickness with time. The negative fractional changes imply a net thinning of resistance vessel walls, predominating at lower values of DBP. Positive fractional changes imply that the vessels become thicker with this predominating at higher values of DBP. One outlying point that has the lowest of both values has been omitted from the graph in order to avoid inconvenient expansion of the scale.



**Figure 3** In this scattergram the x axis shows each patient's serum cyclosporin level averaged over the duration of the study. The y axis shows each patient's logarithmic (geometric) mean wall thickness over all biopsies given in micrometres ( $\mu\text{m}$ ). The wall thickness positively correlates with time averaged cyclosporin concentrations (Spearman's  $\rho = 0.627$ ,  $P = 0.003$ ).

ning Vids-V software and employing a previously described modification of the method of Short.<sup>9</sup> This enabled calculation of mean wall thickness and log wall thickness. The following indices were further derived: gradient of log wall thickness with time; gradient of log wall/lumen ratio with time; and gradient of external diameter with time.

#### STATISTICAL METHODS

The relations between blood pressure and morphometric indices were measured and tested by Spearman's rank correlation method. Where several correlation analyses were carried out on the same set of data, compensation for the multiple tests was made by choosing a more stringent test criterion based on the Bonferroni inequality.

#### Results

##### HISTOLOGICAL APPEARANCES

An example of an intramyocardial artery is shown in fig 1. The coordinates measured are shown superimposed on this artery. In the hypertensive patients the arteries and arterioles showed medial thickening but the intima was always normal. Hyalinisation was never observed.

##### BLOOD PRESSURE

There was a significant difference in diastolic blood pressure between the two groups (Student's  $t$  test,  $P = 0.01$ ; data not shown). The hypertensive patients showed little change and little individual variation in blood pressure with time, whereas the blood pressures of the normotensive group were more variable.

##### BLOOD PRESSURE CORRELATIONS WITH MORPHOMETRIC INDICES

The walls of arteries and arterioles of the high pressure group tended to become thicker with time, whereas those of the normotensive patients tended to become thinner (fig 2), the difference between the gradients of the log wall thickness of the two groups being of marginal

Parametric (Pearson's) and non-parametric (Spearman's) correlation coefficients between various pharmacological, morphometric, and haemodynamic variables

	CSP mean	Log mean W	Mean systolic	Mean diastolic
Pearson's product-moment correlation coefficients:				
Log mean W	0.518			
Mean systolic	-0.152	0.415		
Mean diastolic	-0.075	0.231	0.747	
MAP	-0.114	0.333	0.917	0.950
Spearman's rank correlation coefficients:				
Log mean W	0.618			
Mean systolic	-0.072	0.254		
Mean diastolic	-0.140	0.115	0.812	
MAP	-0.123	0.236	0.922	0.954

CSP mean, time averaged serum cyclosporin concentration (calculated as in fig 3 legend); Log mean W, logarithmic mean of wall thickness over all of the patient's biopsies; Mean systolic, arithmetic mean systolic blood pressure taken over all of each patient's recordings; Mean diastolic, arithmetic mean diastolic blood pressure taken over all of each patient's recordings; MAP, arithmetic mean arterial pressure.

Each correlation coefficient was based on a scattergram (not shown) analogous to those in figures 2 and 3 in which each patient is represented by one point. CSP mean correlated positively with log mean wall thickness, but had only a non-significant negative correlation with the indices of blood pressure.

significance ( $P = 0.045$ ). There were two significant positive correlations between blood pressure and the rate of change of arterial geometry: diastolic blood pressure versus rate of change of vessel wall thickness ( $P = 0.0025$ ; fig 2); mean arterial pressure versus rate of change of vessel wall thickness ( $P = 0.004$ ; not shown). There was no correlation between systolic blood pressure and any morphometric measurement, and there were no other statistically significant differences in any of the morphometric indices between the hypertensive group and the normotensive group (Student's *t* test).

#### EFFECT OF DRUG TREATMENT

The mean serum cyclosporin A concentration correlated with the mean vessel wall thickness ( $P = 0.003$ ; fig 3). Correlations between mean cyclosporin A levels, mean arterial wall thickness, and blood pressure are given in the table. Although mean cyclosporin A concentrations showed a significant positive correlation with mean wall thickness, there was a tendency towards negative correlation between cyclosporin A levels and blood pressure. This suggests that the apparent effect of cyclosporin A on wall thickness was not mediated by blood pressure. There was no significant correlation between any of the morphometric indices and treatment with glucocorticoids or individual antihypertensive agents. There was no correlation between other clinical variables and artery wall thickness.

#### Discussion

Ischaemia is now the most common cause of late cardiac allograft failure. This is believed to be due to transplant associated coronary artery disease, which involves the large epicardial coronary arteries and can be identified by coronary angiography. Changes in small intramyocardial resistance vessels have been neglected. These vessels can only be studied in biopsies. Endomyocardial biopsy, formalin fixation, paraffin embedding, and sectioning are known to cause tissue shrinkage and distortion. We have estimated that there is a 10% linear distortion of small arteries due to sectioning of paraffin embedded endomyocardial biopsies,

suggesting that useful information can be obtained from them.<sup>10</sup> Other workers have reached the same conclusion.<sup>7</sup>

#### EFFECT OF BLOOD PRESSURE ON VESSEL WALL THICKNESS

We have shown that raised blood pressure is associated with medial thickening of intramyocardial coronary arteries and arterioles in cardiac allografts. This agrees with current concepts of the effects of blood pressure on resistance vessels<sup>1,2,4</sup> and with the observed effects of essential hypertension on intramyocardial arteries and arterioles in biopsies of native hearts.<sup>7,8</sup> Artery wall thickening correlated best with diastolic blood pressure, less strongly with mean arterial pressure, and not with systolic blood pressure. This finding is in keeping with the view that intramyocardial coronary resistance arteries are protected from the effects of systolic blood pressure because there is no flow through them during systole.<sup>2</sup> The weaker correlation with mean blood pressure compared with diastolic pressure could be due to a diminution of the correlation from the contribution of systolic blood pressure to the mean arterial pressure value. Overall, our data suggest that raised diastolic pressure causes thickening of small intramyocardial coronary arteries and that these arteries are protected from the effects of systolic blood pressure.

Hyaline arteriosclerosis of intramyocardial coronary arteries was not observed in the hypertensive group. This is in agreement with previous studies of arteriosclerosis.<sup>2</sup> The development of arteriosclerosis may be more dependent on the height of systolic pressure than of diastolic blood pressure; alternatively the development of medial thickening could be more sensitive than arteriosclerosis to pressure. Non-immune binding of plasma proteins, including complement, to proteoglycans in the vessel wall has also been suggested as a possible cause of arteriosclerosis.<sup>11</sup> Histologically visible arteriosclerosis may require a prolonged build up of plasma proteins in the vessel wall; however, the time course of this study was only 15 months, and this period may be too short. The inability to produce hyaline in the resistance arteries of either diabetic or hypertensive animals (personal observation) is in accord with the latter explanation.

The mechanisms underlying the reduction of vessel wall thickness in the normotensive group are unclear. Candidate causes include: cardiac denervation; regression of pre-existing hypertensive changes in donor arteries; and resolution of arterial damage resulting from ischaemia or rejection. Unfortunately, blood pressure readings recorded in the donors before their terminal illness were not usually available. However, blood pressure differences between donor and recipient may clearly affect the ultimate geometry of cardiac resistance vessels.

#### EFFECTS OF DRUG TREATMENT ON VESSEL THICKNESS

Average serum cyclosporin A concentrations showed a strong correlation with arterial wall thickness (fig 3). Since cyclosporin is an estab-

lished cause of systemic hypertension, a possible pathogenic mechanism is immediately apparent.<sup>6</sup> However, our statistical analysis suggests that any effect of cyclosporin on artery structure is unlikely to have been mediated by hypertension. Therefore, either direct or immunological actions of cyclosporin on both vascular smooth muscle and endothelial cells may be important in mediating vessel thickening. Recent experimental work in heterotopic rat cardiac allografts suggests that cyclosporin inhibits the intimal thickening seen in large artery transplant associated coronary artery disease.<sup>12</sup> The effects of cyclosporin on the small subendocardial arterioles examined in this study are likely to have a different pathogenesis, since there were no intimal changes and there was no histological evidence that arterial thickening was related to rejection. Cyclosporin may directly affect vasoconstriction or artery growth. There is evidence that it may increase medial reactivity in liver transplant recipients.<sup>13</sup> In vitro studies show that candidate mechanisms include enhanced contractile responses to angiotensin<sup>14,15</sup> and platelet derived growth factor<sup>15</sup>; increased free intracellular calcium and agonist induced inositol polyphosphate<sup>15</sup>; diminished relaxation in response to nitric oxide generation<sup>16</sup>; and reduced induction of nitric oxide synthase.<sup>17</sup>

It is likely that the aggressive antihypertensive drug regimen employed in cardiac transplant recipients may have reduced the overall degree of medial thickening in the hypertensive group. If so, it may account for the lack of statistically significant differences in the morphometric indices between the hypertensive and normotensive groups.

#### CLINICAL IMPLICATIONS

Intramyocardial arterial and arteriolar thickening, as observed in this study, is likely to have functional implications and may contribute to cardiac allograft ischaemia. For example, thickening of the walls of intramyocardial coronary arterioles in hypertension correlates with increased minimum coronary resistance

and reduced coronary vasodilator reserve.<sup>8</sup> Furthermore, we have shown that measurable arterial thickening occurs despite aggressive post-transplant antihypertensive treatment. New treatments may have to be considered in order to inhibit these small vessel changes if they prove to be clinically important.

- 1 Folkow B. Physiological aspects of primary hypertension. *Physiol Rev* 1982;62:348-79.
- 2 Lindop GBM. The effects of hypertension on the structure of human resistance vessels. In: Swales J D, ed. *Textbook of hypertension*. London: Blackwell Scientific Publications, 1994:663-70.
- 3 Lever AF. Slow pressor mechanisms in vascular hypertrophy: a role for hypertrophy of resistance vessels. *J Hypertens* 1986;4:515-24.
- 4 Gibbons GH, Dzau VJ. Emerging concept of vascular remodelling. *N Engl J Med* 1994;330:1431-8.
- 5 Mulvany MJ. The development and regression of vascular hypertrophy. *J Cardiovasc Pharmacol* 1992;19(suppl 2):S22-7.
- 6 Thompson ME, Shapiro AF, Johnson AM, Reeves R, Itzkoff J, Ginchereau E, et al. New onset hypertension following cardiac transplantation: a preliminary report and analysis. *Transplant Proc* 1983;15:2573-7.
- 7 Schwartzkopff B, Motz W, Knauer S, Frenzel H, Strauer BE. Morphometric investigation of intramyocardial arterioles in right septal endomyocardial biopsy of patients with arterial hypertension and left ventricular hypertrophy. *J Cardiovasc Pharmacol* 1992;20(suppl 1):S12-17.
- 8 Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial arterioles in patients with arterial hypertension. *Circulation* 1993;88:993-1003.
- 9 Short D. Morphology of the intestinal arteriole in chronic human hypertension. *Br Heart J* 1966;28:184-92.
- 10 Boyle JJ, Jenkins J, McKay IC, McPhaden AR, Lindop EBM. An assessment of the distortion of arteries due to sectioning in endomyocardial biopsies. *J Pathol* 1997;181:243-6.
- 11 Gamble CN. The pathogenesis of hyaline arteriosclerosis. *Am J Pathol* 1986;122:410-20.
- 12 Paul LC, Davidoff A, Benediktsson H. Cardiac allograft atherosclerosis in the rat: the effect of histocompatibility factors, cyclosporin and an angiotensin converting enzyme inhibitor. *Transplantation* 1994;57:1767-72.
- 13 Potocnik SJ, Phillips PA, Hardy KJ. Human resistance artery reactivity is altered by liver transplantation and treatment with cyclosporin A. *Transplant Proc* 1992;24:2254-5.
- 14 Auch-Schwelk W, Bossaller C, Gotze S, Thelen J, Fleck E. Endothelial and vascular smooth muscle function after chronic treatment with cyclosporin A. *J Cardiovasc Pharmacol* 1993;21:435-40.
- 15 Locher R, Huss R, Vetter W. Potentiation of vascular smooth muscle cell activity by cyclosporin A. *Eur J Clin Pharmacol* 1991;41:297-301.
- 16 Verbeke M, Van de Voorde J, de Ridder L, Lameire N. Functional analysis of vascular dysfunction in cyclosporin treated rats. *Cardiovasc Res* 1994;28:1152-6.
- 17 Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. *Hypertension* 1995;25:764-8.